11:41 AM EST - Crescita Therapeutics Inc. : Has received positive topline results from a Phase 2 clinical trial in patients with plaque psoriasis (MiCal 1) conducted by its partner, Ferndale Laboratories, Inc. (Ferndale), in conjunction with a leading U.S. Contract Research Organization. The Trial demonstrated statistical significance in the achievement of its primary endpoint. Crescita Therapeutics Inc.
shares T.CTX are trading up $0.06 at $0.66.
